Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CNS Pharmaceuticals, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CNSP
Nasdaq
2830
www.cnspharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
- Dec 5th, 2024 2:10 pm
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
- Nov 25th, 2024 2:00 pm
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
- Nov 18th, 2024 1:55 pm
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
- Nov 15th, 2024 2:10 pm
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
- Nov 4th, 2024 2:15 pm
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
- Nov 1st, 2024 2:00 pm
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
- Oct 23rd, 2024 6:50 pm
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
- Oct 10th, 2024 1:00 pm
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
- Oct 8th, 2024 1:15 pm
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
- Sep 23rd, 2024 1:00 pm
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
- Sep 12th, 2024 1:00 pm
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 4th, 2024 1:05 pm
IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
- Sep 3rd, 2024 12:00 pm
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
- Aug 27th, 2024 1:10 pm
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
- Aug 22nd, 2024 1:15 pm
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Aug 15th, 2024 12:00 pm
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
- Jul 30th, 2024 11:00 am
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
- Jul 25th, 2024 1:05 pm
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
- Jul 16th, 2024 1:15 pm
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
- Jul 3rd, 2024 3:10 pm
Scroll